1921
Volume 76, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Tafenoquine was used to treat malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine-tolerant strains of malaria.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.76.494
2007-03-01
2017-11-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/76/3/0760494.html?itemId=/content/journals/10.4269/ajtmh.2007.76.494&mimeType=html&fmt=ahah

References

  1. Baird JK, Rieckmann KH, 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19 : 115–120.
  2. Kitchener S, Rieckmann K, 2001. Malaria in the ADF. ADF Health 2 : 17–18.
  3. Kitchener S, Nasveld P, Bennett S, Torresi J, 2005. Adequate primaquine for vivax malaria. J Travel Med 12 : 133–135.
  4. Bruecker RP, Lasseter KC, Lin ET, Schuster BG, 1998. First-time-in-humans safety and pharmacokinetics of WR238605, a new antimalarial. Am J Trop Med Hyg 58 : 645–649.
  5. Kitchener S, 2002. Epidemiology of malaria from East Timor among Australian Defence Force personnel. Trans R Soc Trop Med Hyg 96 : 376–377.
  6. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, 1960. Mitigation of the haemolytic effect of primaquine and enhancement of it’s action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ 22 : 621–631.
  7. Kocisko DA, Walsh DS, Eamsila C, Edstein MD, 2000. Measurement of tafenoquine (WR 238605) in human plasma, and venous and capillary blood by high-pressure liquid chromatography. Ther Drug Monit 22 : 184–189.
  8. Nasveld P, Kitchener S, Edstein M, Rieckmann K, 2002. Comparison of tafenoquine (WR238605) and primaquine in the terminal prophylaxis of vivax malaria in Australian Defence Force personnel. Trans R Soc Trop Med Hyg 96 : 683–684.
  9. Walsh DS, Wilairatana P, Tang DB, Heppner DG, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S, 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 39 : 1095–1103.
  10. Edstein MD, Kocisko DA, Walsh DS, Eamsila C, Charles BG, Rieckmann KH, 2003. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers on monthly prophylaxis. Clin Infect Dis 37 : 1654–1658.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.76.494
Loading
/content/journals/10.4269/ajtmh.2007.76.494
Loading

Data & Media loading...

  • Received : 25 Sep 2006
  • Accepted : 21 Nov 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error